A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Institut Claudius Regaud
Rutgers, The State University of New Jersey
AstraZeneca
M.D. Anderson Cancer Center
Erasmus Medical Center
TScan Therapeutics, Inc.
Rondo Therapeutics
Regeneron Pharmaceuticals
Nuvectis Pharma, Inc.
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
Carisma Therapeutics Inc
Advaxis, Inc.
ZielBio, Inc.
Adaptimmune
Queensland Centre for Gynaecological Cancer
University of South Alabama
University Health Network, Toronto
Assiut University
M.D. Anderson Cancer Center
Quest PharmaTech Inc.
KitovPharma
Ontario Clinical Oncology Group (OCOG)
Edward-Elmhurst Health System
National Institutes of Health Clinical Center (CC)
Queensland Centre for Gynaecological Cancer
National Institutes of Health Clinical Center (CC)
Pierian Biosciences
AIO-Studien-gGmbH
Universitätsmedizin Mannheim
Santa Maria Biotherapeutics
Edward-Elmhurst Health System
Novartis
Celldex Therapeutics
University of Miami
Memorial Sloan Kettering Cancer Center
Precision Therapeutics
M.D. Anderson Cancer Center
UNICANCER
National Institutes of Health Clinical Center (CC)